Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion
- PMID: 6381007
- DOI: 10.2337/diacare.7.4.338
Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion
Abstract
In order to evaluate the metabolic consequences of a 2-h nocturnal interruption of continuous subcutaneous insulin infusion (CSII), seven insulin-dependent diabetic patients without residual insulin secretion were investigated. The changes in blood glucose, plasma free insulin, glucagon, free fatty acids, and 3-hydroxybutyrate (3 OH-B) concentrations have been compared during two randomized tests carried out either during the normal functioning of a Mill-Hill pump from 10 p.m. to 8 a.m. (1.00 +/- 0.06 U insulin/h, keeping adequate metabolic control) or during the same conditions but with a deliberate arrest of the pump between 11 p.m. and 1 a.m. Considering the value recorded at 11 p.m. as reference, interruption of the insulin infusion resulted in: (1) a rapid (already significant after 1 h) and sustained (maximal fall: --12.5 +/- 2.5 mU/L at 3 a.m.) decrease in plasma free insulin; (2) a delayed (significant after 4 h) and linear rise in blood glucose (maximal increase: + 4.0 +/- 1.3 mmol/L at 5 a.m.); (3) an early (significant at midnight) and prolonged rise in plasma free fatty acids (+ 387 +/- 148 mumol/L at 3 a.m.); (4) a delayed (significant after 3 h) and sustained increase in plasma 3 OH-B (+ 347 +/- 88 mumol/L at 3 a.m.); and (5) no significant changes in plasma glucagon. Thus, a 2-h interruption of CSII in resting nocturnal conditions is sufficient to induce significant, delayed, and sustained metabolic alterations in C-peptide-negative patients despite good baseline blood glucose control. Resetting the pump at its basal rate is insufficient to quickly restore adequate circulating insulin levels and effectively counteract the metabolic disturbances. The efficacy of a bolus insulin injection in these conditions should be evaluated.
Similar articles
-
Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.Diabetologia. 1989 Nov;32(11):801-9. doi: 10.1007/BF00264911. Diabetologia. 1989. PMID: 2687064
-
A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control.Diabetologia. 1983 May;24(5):314-8. doi: 10.1007/BF00251815. Diabetologia. 1983. PMID: 6347779 Clinical Trial.
-
U-100 insulin gives some protection against metabolic deterioration due to CSII interruption.Diabetes Care. 1987 Nov-Dec;10(6):707-11. doi: 10.2337/diacare.10.6.707. Diabetes Care. 1987. PMID: 3322727
-
Prevention of metabolic alterations by insulin supplements administered either before or after 2-h nocturnal interruption of CSII.Diabetes Care. 1987 Sep-Oct;10(5):567-72. doi: 10.2337/diacare.10.5.567. Diabetes Care. 1987. PMID: 3315513 Clinical Trial.
-
The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level.J Clin Endocrinol Metab. 1996 May;81(5):1975-8. doi: 10.1210/jcem.81.5.8626867. J Clin Endocrinol Metab. 1996. PMID: 8626867
Cited by
-
Innovations in technology for the treatment of diabetes: clinical development of the artificial pancreas (an autonomous system).J Diabetes Sci Technol. 2011 May 1;5(3):804-26. doi: 10.1177/193229681100500336. J Diabetes Sci Technol. 2011. PMID: 21722597 Free PMC article.
-
Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience.Diabetologia. 1989 Jul;32(7):421-6. doi: 10.1007/BF00271261. Diabetologia. 1989. PMID: 2509271
-
Pharmacokinetics of insulin. Implications for continuous subcutaneous insulin infusion therapy.Clin Pharmacokinet. 1985 Jul-Aug;10(4):303-14. doi: 10.2165/00003088-198510040-00002. Clin Pharmacokinet. 1985. PMID: 3899451 Review.
-
Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.Diabetologia. 1989 Nov;32(11):801-9. doi: 10.1007/BF00264911. Diabetologia. 1989. PMID: 2687064
-
Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension.Diabetes Care. 2010 May;33(5):1013-7. doi: 10.2337/dc09-2303. Epub 2010 Mar 3. Diabetes Care. 2010. PMID: 20200307 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials